Scailyte AG announces a partnership with AliveX Biotech to jointly advance AI-driven multi-omics biomarker and target discovery
May 13, 2022
Scailyte, a single-cell AI biomarker discovery company and AliveX Biotech, a leader in combining multi-omics data with computational biology and AI to identify novel biomarkers and targets in immune-mediated diseases, announce a strategic partnership to accelerate the development of next-generation therapies in oncology and autoimmune diseases.
The companies will create a joint target and biomarker discovery workflow, leveraging their expansive network of clinical collaborators, AliveX's AI and multi-omics platform solutions and its powerful proprietary immuno-profiling and decoding technologies, as well as Scailyte's AI-driven single-cell analytics biomarker discovery platform ScaiVision™ to serve the diverse and complex needs of Pharma and Biotech companies. The joint platform will enable unprecedented discovery and validation power for biomarker discovery thanks to AliveX Biotech's expertise from intelligent AI-driven hypothesis generation to broad multi-omics analytics capabilities, and the ability of ScaiVision™ to detect complex, ultra-sensitive and predictive molecular signatures in biological samples.
The joint workflow will focus on applications within immune-mediated diseases, such as qualification and stratification of patients for clinical trials, analysis of trial results at deep cellular level, as well as digital disease modeling and end-to-end multi-omics analysis for target discovery.
The companies kick-start the outreach to pharmaceutical and biotech companies, aiming to set up the first pilot projects in Q2-2022.
"We are delighted to announce this partnership with AliveX Biotech. Precision medicine in oncology and autoimmunity is still a challenge today, which requires access to high quality samples and data, full mastery and exploitation of the most advanced multi-omics approaches, including single-cell technologies and analytics, coupled with AI discovery engines. With our combined expertise in single-cell technologies, multi-omics analytics and fit-for-purpose AI algorithms, we will be able to offer fully tailored, sensitive and robust biomarker discovery solutions to truly bolster the development of effective and safe immunotherapies, from patients and for patients" said Corinne Solier, COO at Scailyte AG.
"We are thrilled to partner with Scailyte AG. Scailyte's powerful single cell AI-powered platform and AliveX's end-to-end AI immunology platform will be important assets in the partnership." said Dimitris Christodoulou, Chief Strategy Officer and co-founder at AliveX, emphasizing that "We believe the partnership will enable us to bring forward significant value amounting to 'more than the sum of our parts'. Our combined holistic approach leverages both bulk and single cell data as well as state-of-the-art computational biology approaches that generate novel insights, enabling higher precision in biomarker and drug target discovery which in turn leads to higher success rates in R&D and clinical trials."
More than the sum
of its parts
contact@alivexbiotech.com
Zeunerstrasse 9, 8037 Zurich
